Researchers probe consequences of androgen deprivation for prostate cancer.
Friedrich
M J
MJ
D000726:Androgen Antagonists / Q000009:adverse effects*; D000728:Androgens / Q000378:metabolism; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003072:Cognition Disorders / Q000139:chemically induced; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D020249:Hormone Replacement Therapy; D006801:Humans; D007006:Hypogonadism / Q000139:chemically induced; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D012306:Risk; D013739:Testosterone / Q000627:therapeutic use
D000726:Androgen Antagonists; D000728:Androgens; D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone